Opiate Treatment in Depression Refractory to Antidepressants and Electroconvulsive Therapy

Nyhuis, Peter W.; Gastpar, Markus; Scherbaum, Norbert

doi:10.1097/jcp.0b013e31818638a4

Cited by 80 publications

(59 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nyhuis reported three patients who had failed electroconvulsive treatment but had a robust response to buprenorphine and oxycodone [5,6]. The study results were consistent with the observation that in some cases of treatment refractory depression opiates were more effective than ECT.…”

Section: Antidepressant Effects Of Endorphin Agonists: Animal and CLIsupporting

confidence: 81%

See 1 more Smart Citation

Endorphin agonists for psychiatric disorders

Salerian¹

2016

Phys Med Rehabil Res

View full text Add to dashboard Cite

Endorphins and endorphin agonists play a crucial role in the neural modulation of mood, anxiety, pain and addiction.Historical, experimental and clinical data strongly support the potential benefits of opiates for severe depression, addictive disorders, pain and psychosis. Recent studies have also elucidated a crucial mechanism of treating depression-enhancing prefrontal cortex influence and dampening limbic and sub cortical influencessimilar to the neurobiological actions of endorphin agonists.Despite much publicity of an alleged causal association between prescription pain medications and an epidemic of overdose deaths, no scientific evidence exists to support a causal link between prescription opiates and the overdose deaths.Despite concerns of addiction and misuse potential further research to study endorphin agonists for diverse psychiatric disorders seems warranted.Correspondence to: Alen J Salerian, Salerian Center for neuroscience and pain, 8409 Carlynn Dr.,

show abstract

Section: Antidepressant Effects Of Endorphin Agonists: Animal and CLIsupporting

confidence: 81%

“…There is also a growing body of behavioral and pharmacological evidence linking the opioid system to the pathophysiology of depression, addiction, chronic pain, psychoses and other psychiatric disorders [4][5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Endorphin agonists for psychiatric disorders

Salerian¹

2016

Phys Med Rehabil Res

View full text Add to dashboard Cite

show abstract

“…Despite its limitations, this study offers evidence to suggest that disruption of opiate treatment might have-independent of any another possible influence-contributed to the current dual epidemics [41][42][43][44][45][46].…”

Section: Limitations Of This Study Include the Followingmentioning

confidence: 99%

Dual epidemics of deaths by heroin overdose and suicide

Salerian¹

2017

Clin Res Trials

View full text Add to dashboard Cite

show abstract

“…In addition, at higher concentrations, BPN is an antagonist at the delta opioid receptor (DOR) and a partial agonist at the opioid receptorlike 1 (ORL-1) receptor (Cowan, 2007;Lutfy and Cowan, 2004). In a handful of clinical studies, low doses of BPN produced impressive alleviation of depressive symptoms in patients that were considered treatment-resistant within 1 week of initiating administration (Bodkin et al, 1995;Nyhuis et al, 2008). Subsequently, a study with geriatric treatment-resistant MDD patients showed a significant mood-elevating effect of BPN after 1 week of treatment (Karp et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors

Falcón

Browne

Leon

et al. 2016

Neuropsychopharmacol

105

View full text Add to dashboard Cite

Previous studies have identified potential antidepressant effects of buprenorphine (BPN), a drug with high affinity for mu opioid receptor (MORs) and kappa opioid receptors (KORs) and some affinity at delta opioid receptor (DOR) and opioid receptor-like 1 (ORL-1) receptors. Therefore, these studies examined which opioid receptors were involved in BPN's effects on animal behavior tests sensitive to antidepressant drugs. The acute effects of BPN were tested in the forced swim test (FST) using mice with genetic deletion of individual opioid receptors or after pharmacological blockade of receptors. For evaluating the effects of BPN on chronic stress, separate groups of mice were exposed to unpredictable chronic mild stress (UCMS) for 3 weeks and treated with BPN for at least 7 days before behavioral assessment and subsequent measurement of Oprk1, Oprm1, and Pdyn mRNA expression in multiple brain regions. BPN did not reduce immobility in mice with KOR deletion or after pretreatment with norbinaltorphimine, even though desipramine remained effective. In contrast, BPN reduced immobility in MOR and DOR knockout mice and in mice pretreated with the ORL-1 antagonist JTC-801. UCMS reduced sucrose preference, decreased time in the light side of the light/dark box, increased immobility in the FST and induced regionspecific alterations in Oprk1, Oprm1, and PDYN mRNA expression in the frontal cortex and striatum. All of these changes were normalized following BPN treatment. The KOR was identified as a key player mediating the effects of BPN in tests sensitive to antidepressant drugs in mice. These studies support further development of BPN as a novel antidepressant.

show abstract

Opiate Treatment in Depression Refractory to Antidepressants and Electroconvulsive Therapy

Cited by 80 publications

References 11 publications

Endorphin agonists for psychiatric disorders

Endorphin agonists for psychiatric disorders

Dual epidemics of deaths by heroin overdose and suicide

Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors

Contact Info

Product

Resources

About